Market Overview

Wells Fargo Turns Bullish On Revance Therapeutics After Meeting With Management

Share:
Wells Fargo Turns Bullish On Revance Therapeutics After Meeting With Management

Earlier this month, Revance Therapeutics Inc (NASDAQ: RVNC) named Mark Foley as its new CEO.

The addition of a commercial-focused CEO, with experience in unlocking shareholder value in aesthetics, is a “major positive,” according to Wells Fargo.

The Analyst

Wells Fargo’s Jacob Hughes upgraded Revance Therapeutics from Market Perform to Outperform raising the price target from $12.50 to $20.

The Thesis

Mark Foley’s strong track record of commercial success in aesthetics is particularly important, as Revance Therapeutics is transitioning from a development stage to commercialization, Hughes said in the upgrade note.

He added that the new CEO will also focus on reducing the company’s operating expenses to curb the rate of cash burn.

Hughes mentioned that Revance Therapeutics had several catalysts over the next six to twelve months, the most notable of which is a biologics license application (BLA) submission for DaxibotulinumtoxinA (DAXI) for treatment of glabellar lines by the end of November.

“Revance growth potential is significant in a multi-billion neurotoxins market, targeting both aesthetic and therapeutic indications,” the analyst wrote. He added that these markets were poised for continued expansion and that disruption from the merger between Allergan plc (NYSE: AGN) and AbbVie Inc (NYSE: ABBV) could create opportunities to take share.

Price Action

Shares of Revance Therapeutics rose slightly to close trading at $15.42 on Tuesday.

Latest Ratings for RVNC

DateFirmActionFromTo
Dec 2019Initiates Coverage OnBuy
Oct 2019UpgradesMarket PerformOutperform
Jun 2019Initiates Coverage OnOverweight

View More Analyst Ratings for RVNC
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Upgrades Price Target Management Analyst Ratings General

 

Related Articles (AGN + ABBV)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
TOLGoldman SachsInitiates Coverage On42.0
KBHGoldman SachsInitiates Coverage On36.0
YEXTSunTrust Robinson HumphreyMaintains28.0
LHCGSunTrust Robinson HumphreyMaintains160.0
DLRSunTrust Robinson HumphreyMaintains140.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Astros-Nationals Game 7 Tickets: How They Stack Up Against This Decade's Other Championship Games

PreMarket Prep: A Few Dogs Are Barking, Fading A Herd Of Grubhub Analysts